Potentiation of antiproliferative effects of monoclonal antibody Lym-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with gamma-interferon and tumor necrosis factor

J Immunother Emphasis Tumor Immunol. 1995 Nov;18(4):221-30. doi: 10.1097/00002371-199511000-00003.

Abstract

A type I ribosome inactivating protein, gelonin, was linked to Lym-1, a murine monoclonal antibody reactive with a polymorphic determinant of class II HLA-DR histocompatibility leukocyte antigen (HLA) on human lymphoma cells, via a disulfide linkage using the heterobifunctional cross-linking agent, N-succinimidyl-3-(2-pyridyldithio) propionate. This immunotoxin was purified from unreacted gelonin and unconjugated Lym-1 by fast protein liquid chromatography using sephacryl S-300 gel filtration and blue sepharose affinity gradient separation. Binding of Lym-1-gelonin immunoconjugate to human Raji Burkitt's lymphoma cells was demonstrated by indirect immunofluorescence using flow cytometry. Lym-1-gelonin was very active in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium salt and sulforhodamine B in vitro cytotoxicity assays against the Raji lymphoma cell line and confirmed the fact that monoclonal antibody Lym-1 internalizes into human lymphoma cells. A weaker cytostatic antiproliferative effect was also noted for unconjugated Lym-1. gamma-interferon augmented the antiproliferative effects of Lym-1-gelonin conjugate and unconjugated Lym-1, by having a direct cytotoxic effect on the Raji cells. Tumor necrosis factor-alpha also enhanced the antiproliferative effect of unconjugated Lym-1, but did not significantly augment the cytotoxic activity of the Lym-1-gelonin conjugate. These results suggest that anti-HLA class II monoclonal antibodies may be useful in constructing immunotoxins for the treatment of human lymphomas and leukemias expressing HLA class II antigens, and that unconjugated anti-HLA class II monoclonal antibodies may be therapeutically useful in conjunction with recombinant cytokines, especially gamma-interferon.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Antibodies, Monoclonal / metabolism
  • Antibodies, Monoclonal / pharmacology*
  • Antineoplastic Agents, Phytogenic / metabolism
  • Antineoplastic Agents, Phytogenic / pharmacology*
  • Binding Sites, Antibody
  • Burkitt Lymphoma / drug therapy*
  • Burkitt Lymphoma / metabolism
  • Burkitt Lymphoma / pathology
  • Cells
  • Drug Synergism
  • Growth Inhibitors / pharmacology*
  • Growth Inhibitors / toxicity
  • Humans
  • Immunoconjugates / isolation & purification
  • Immunoconjugates / metabolism
  • Immunoconjugates / pharmacology*
  • Interferon-gamma / pharmacology*
  • Mice
  • Plant Proteins / metabolism
  • Plant Proteins / pharmacology*
  • Ribosome Inactivating Proteins, Type 1
  • Tumor Cells, Cultured
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Phytogenic
  • Growth Inhibitors
  • Immunoconjugates
  • Plant Proteins
  • Ribosome Inactivating Proteins, Type 1
  • Tumor Necrosis Factor-alpha
  • GEL protein, Gelonium multiflorum
  • Interferon-gamma